Clinical trial investigating aficamten meets primary endpoint in obstructive hypertrophic cardiomyopathy
Even though mortality and hospitalization rates have improved, the quality of life for those living with hypertrophic cardiomyopathy (HCM) can be compromised with limiting symptoms such as exertional dyspnea and decreased ...
May 13, 2024
0
38
